The equity research house is bullish about its investment case: “We think good market momentum and further market share gains resulting in the ramp-up of new contracts will support sales growth in the coming 5-10 years (CAGR of 10% for 2023-30 and 6% for 2030-35).

“Meanwhile, we model an underlying Ebit CAGR of 13% for 2023-30 and 9% for 2030-35,” which implies a doubling in revenues by 2030, and a doubling in Ebit by mid-2028.

Its prospects are boosted by strong tailwinds ...

Subscription required for Premium stories

In order to view the entire article please login with a valid subscription below or register an account and subscribe to Premium

Or buy full access to this story only for £15.00

Please login to activate the purchase link or sign up here to register an account

Premium subscriber
New Premium subscriber REGISTER

Comment on this article


You must be logged in to post a comment.